PressDecember 1, 2025 Numinus provides corporate update amid TSX delisting review and auditor turnover
PressNovember 26, 2025 Optimi Health selected to supply MDMA for MAPS Israel's 168-patient PTSD trial
PressNovember 18, 2025 MindMed presents at Jefferies Global Healthcare Conference amid MM120 Phase 3 push
PressNovember 17, 2025 Bright Minds expands scientific advisory board to support BMB-101 and new Prader-Willi program
PressNovember 13, 2025 MindBio's Phase 2b take-home LSD microdosing trial underperforms placebo in major depression
PressNovember 13, 2025 Cybin reports quarterly results and clinical progress across CYB003 and CYB004 programs
PressNovember 10, 2025 AtaiBeckley posts positive Phase 2b open-label extension data for BPL-003 in treatment-resistant depression
PressNovember 6, 2025 GH Research reports Q3 2025 results with $293.9 million cash and durable 5-MeO-DMT data
PressOctober 28, 2025 Delix reports positive Phase 1b data for non-hallucinogenic DLX-001 and FDA clearance of at-home Phase 2
PressOctober 23, 2025 Silo Pharma updates SPC-15 PTSD program and adds digital-asset treasury strategy
PressOctober 16, 2025 FDA grants Breakthrough Therapy designation to BPL-003 for treatment-resistant depression
PressSeptember 24, 2025 FDA approves NRx suitability petition for preservative-free ketamine strength
PressSeptember 23, 2025 atai and Beckley report positive Phase 2a two-dose BPL-003 data in treatment-resistant depression
PressSeptember 18, 2025 Colorado advisory board votes to recommend adding ibogaine to regulated healing centers
PressSeptember 18, 2025 atai awarded NIH grant of up to $11.4 million for non-hallucinogenic opioid use disorder program
